The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|November 21, 2019
Fujifilm Expands Gene Therapy CDMO Capacity
Author(s)Pharmaceutical Technology Editors
Fujifilm Diosynth Biotechnologies will add a new building, including gene therapy laboratories, to its facility in College Station, TX.
Advertisement
Fujifilm Corporation will make a capital investment of approximately 13 billion yen (approximately $120 million USD) in the gene therapy field to further expand its contract development and manufacturing business, Fujifilm Diosynth Biotechnologies (FDB), the company announced in a Nov. 14, 2019 press release. As part of this investment, the company will spend approximately $55 million USD to establish a new Gene Therapy Innovation Center adjacent to FDB’s existing cGMP gene therapy manufacturing facility in College Station, TX.
The new Innovation Center will have dedicated gene therapy laboratories. The 6000-m2 laboratories will house upstream, downstream, and analytical development technologies and will be operational in the fall of 2021.
“We expect to break ground in the first quarter of 2020,” said Gerry Farrell, COO at Fujifilm Diosynth Biotechnologies, Texas, in the press release. “This new facility will triple our gene therapy development capabilities and will add approximately 100 jobs to our Texas Campus.”
Fujifilm also announced that additional investments will expand FDB’s gene therapy cGMP capacity, including new cleanrooms and the expansion of its upstream capacity with eight new single-use bioreactors. The site has been offering gene therapy fill/finish services for both clinical and commercial products since early 2019. The first stage of the manufacturing expansion is expected to be completed and in operation by the spring of 2021.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Advertisement
Advertisement